Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Juni 2022 07:00 ET | Quelle: Xenikos B.V.

Xenikos Enrolls First Patient in Global Pivotal Phase 3 Study Evaluating T-Guard® in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Study Designed to Evaluate Whether T-Guard is Superior to Ruxolitinib in Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host DiseasePreliminary Results Expected First Half of...
22. September 2021 07:00 ET | Quelle: Xenikos B.V.

Xenikos Appoints Hassan Aly, MD, PhD as Chief Medical Officer

NIJMEGEN, The Netherlands, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune...
08. September 2021 07:00 ET | Quelle: Xenikos B.V.

Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor

NIJMEGEN, the Netherlands, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders,...
19. Juli 2021 02:00 ET | Quelle: Xenikos B.V.

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives

Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second...